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T
he editorial this month was 
triggered by a discussion among 
the editors at PLoS Medicine 
about whether or not we should, as a 
medical journal, be publishing papers 
on the use of smokeless tobacco (snus), 
the topic of the debate by Gartner, 
Chapman, and colleagues [1]). At one 
end of the spectrum of views expressed, 
one editor argued that we should not 
give the topic room in the journal at all, 
because even discussion of the use of 
snus simply plays into the hands of the 
tobacco industry, which has a notorious 
history of doing anything it can to 
addict people to tobacco. At the other 
end of the spectrum, another editor 
pointed out that since snus is associated 
with less risk to health than cigarettes, 
a discussion of its use as a harm 
reduction measure is an appropriate 
topic for a medical journal. On this 
topic, the editors simply could not 
come to an agreement. (Another such 
topic, incidentally, is that of qualitative 
research, on which more in future.)
Don’t journals have a duty to give all 
sides of a debate? That was certainly 
the argument that the BMJ put 
forward when it published a paper that 
concluded that harm caused by passive 
smoking had been overestimated [2]. 
Unfortunately, that paper turned 
out not to be free of bias and may in 
fact have been part of the tobacco 
industry’s ongoing attempt to discredit 
evidence of the harms caused by passive 
smoking [3]. In trying to be fair, the 
BMJ may have been the victim itself 
of cynical maneuvering by an industry 
not known for its interest in playing by 
the rules in promotion of its products. 
By publishing papers such as the one 
on snus, could we be legitimizing 
a debate that at best can only shift 
tobacco dependence from one product 
to another? Should we only publish 
papers that point out the wrongdoing 
of the tobacco industry (e.g., [4]) or 
advocate the abolition of all tobacco 
products?
No PLoS Medicine editor would argue 
that proﬁ  ting from an addiction that 
severely impairs health is ethical, and 
none of us would dispute that ceasing 
to use tobacco is better than switching 
to snus. The issue is whether, in a world 
where many people die from their 
tobacco addiction without overcoming 
it, we should give room to the opinion 
that switching to snus, although not 
better than quitting, may be better in 
terms of short-term health outcomes 
than continuing to smoke.
In respect for honest differences of 
opinion, we are ending this editorial 
without a bottom line. Do papers on 
smokeless tobacco serve a legitimate 
public health interest? We’d like to 
seek the opinions of our readers: what 
do you think?  
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